AstraZeneca PLC (LON:AZN – Get Rating)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of £112.99 ($140.54) and traded as high as £121.86 ($151.57). AstraZeneca shares last traded at £120.34 ($149.68), with a volume of 1,381,910 shares trading hands.
Analyst Upgrades and Downgrades
Several brokerages recently commented on AZN. The Goldman Sachs Group set a GBX 6,950 ($86.44) target price on AstraZeneca in a research report on Thursday, February 9th. Credit Suisse Group set a £118 ($146.77) price target on AstraZeneca in a report on Friday, February 10th. Berenberg Bank set a £124 ($154.23) price target on AstraZeneca in a report on Thursday, March 16th. JPMorgan Chase & Co. increased their price target on AstraZeneca from £135 ($167.91) to £140 ($174.13) in a report on Friday, April 28th. Finally, Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Wednesday, April 12th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of £119.32 ($148.41).
AstraZeneca Stock Down 0.0 %
The company has a debt-to-equity ratio of 90.68, a current ratio of 0.90 and a quick ratio of 0.59. The stock has a fifty day moving average price of £116.43 and a two-hundred day moving average price of £112.99. The company has a market cap of £186.53 billion, a P/E ratio of 4,993.36, a price-to-earnings-growth ratio of 2.32 and a beta of 0.18.
Insider Transactions at AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.